Condition: Endometrial Cancer · Sponsor: Alliance Foundation Trials, LLC.
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
This description comes directly from the study's public registry record.
Quality Management and Compliance · 617-732-8727 · ClinicalTrials.Queries@alliancefoundationtrials.org
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Active Not Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Active Not Recruiting |
| Medstar Georgetown Cancer Institute | Washington D.C., District of Columbia, United States | Active Not Recruiting |
| Mount Sinai Comprehensive Cancer Center | Miami Beach, Florida, United States | Active Not Recruiting |
| University of Chicago | Chicago, Illinois, United States | Active Not Recruiting |
| University of Kansas Cancer Center | Westwood, Kansas, United States | Active Not Recruiting |
| Maine Medical Center | Scarborough, Maine, United States | Active Not Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Active Not Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Active Not Recruiting |
| Washington University School of Medicine Siteman Cancer Center | St Louis, Missouri, United States | Withdrawn |
| Nebraska Methodist Hospital | Omaha, Nebraska, United States | Active Not Recruiting |
| Englewood Health | Englewood, New Jersey, United States | Active Not Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04486352